ArticleScientific reports2025
Understanding of the characteristics of fibroblasts in ischemic cardiomyopathy using single-nucleus RNA sequencing.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting Cardiac Fibroblast Plasticity for Antifibrotic and Regenerative Therapy in Heart Failure.Cells · 2026Review
- Decoding cardiac metabolic reprogramming through single-cell multi-omics: from mechanisms to therapeutic applications.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Fibroblasts play a crucial role in the development and progression of heart failure in many heart-related diseases. However, the contributions of fibroblast and its subtypes to the pathogenesis of ischemic cardiomyopathy (ICM) remain unclear. In this study, we analyzed single-nucleus RNA sequencing data from cardiac tissues of seven ICM patients with heart failure and eight control subjects. Our findings indicate that, compared to controls, fibroblasts from ICM patients exhibit dysregulation of genes associated with cell-substrate adhesion and matrix or collagen fibril organization. We further identified five fibroblast subtypes, designated as FB1 through FB5, with FB3 exhibiting the highest frequency in ICM. Pseudotime trajectory analysis further revealed an evolutionary progression of fibroblasts from FB1/FB2 toward FB3. Differential gene expression analysis of FB3 highlighted several subtype-specific genes, such as NTM, THBS4, NRK, NAV2, and PLA2G5. Furthermore, intercellular interaction analysis revealed that FB3 exhibits weakened interactions with other cells under ICM. Specifically, signaling interactions involving ANGPTL and COLLAGEN are reduced, whereas pathways mediated by THBS, NRXN, and APP are strengthened. These results provide valuable insights into the fibroblast microenvironment and elucidate the pathological mechanisms underlying ICM, laying a theoretical foundation for the identification of novel therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.